Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
SGMT 11.26.2024
Drug:denifanstat-MASH denifanstat
Diseases:metabolic dysfunction associated steatohepatitis
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
About Gravity Analytica
Recent News
- 01.13.2025 - FASN inhibitor
- 01.13.2025 - Denifanstat showed anti-fibrotic effect both on conventional and digital pathology in a metabolic dysfunction-associated steatohepatitis (MASH) Phase 2b trial (FASCINATE-2)
- 01.06.2025 - Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
Recent Filings
A webcast of the presentation will be available in the Investors & Media section of Sagimet’s website atwww.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visitwww.sagimet.com.
Contact:Joyce AllaireLifeSci Advisorsjallaire@lifesciadvisors.com
Source:
Source: Sagimet Biosciences Inc.